With its long-standing partnership with Sanofi in its final days, Regeneron is in a belt-tightening phase as it prepares for its new reality. Now, the first blow has landed with some of the New York-based drugmaker’s staff being shown the door.
Regeneron will eliminate 15 field and supporting staff positions in February as it reworks its longstanding partnership with Sanofi for PCSK9 med Praluent and rheumatoid arthritis med Kevzara. According to a New York State WARN notice Dec. 20, the company is expected to lay off those staffers Feb. 18.
A Regeneron spokeswoman could not be reached for comment by press time.
Whitepaper
Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D
Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.
In early December, Sanofi and Regeneron announced they would restructure their 12-year-old partnership into a royalty-based agreement for Praluent and Kevzara, with Regeneron taking over U.S. rights to the former and Sanofi snagging global rights to the latter.
twisted family secrets full movie limpiando culo snigdha sinha video anyxvideos.com sex slave full video view here ksb besaba com katrina reyal sex garden on house wife rape 1st sex young xnxx-br.com bd bdsexvideo sasur bhou sex romance bluepornsex video xxx vide0 gan czech teen swallow money گایدن افقانی anushka sharma ki video vdeo xxx japaeb fetishwife clare